Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Human papillomavirus vaccine recombinant quadrivalent - Serum Institute of India

Drug Profile

Human papillomavirus vaccine recombinant quadrivalent - Serum Institute of India

Alternative Names: Human papillomavirus (types 6, 11, 16, 18) L1 virus-like particle vaccine - Serum Institute of India; Human papillomavirus (types 6, 11, 16, 18) L1 VLP vaccine - Serum Institute of India; Human papillomavirus quadrivalent (types 6, 11, 16, 18) recombinant vaccine - Serum Institute of India; qHPV vaccine - Serum Institute of India; Recombinant quadrivalent HPV vaccine - Serum Institute Of India; SIIPL qHPV vaccine; Tetravalent HPV vaccine - Serum Institute of India

Latest Information Update: 11 Mar 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Serum Institute of India
  • Class Cancer vaccines; Papillomavirus vaccines; Synthetic vaccines; Virus-like particle vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II/III Human papillomavirus infections

Most Recent Events

  • 11 Mar 2021 Phase II/III development in Human papillomavirus infections is ongoing in India (CTRI2018-06-014601)
  • 16 Jul 2018 Phase-II/III clinical trials in Human papillomavirus infections (Prevention, In children, In adolescents, In adults) in India (IM) (CTRI2018-06-014601)
  • 18 Jul 2017 Serum Institute of India completes a phase I trial in Human papillomavirus infections (Prevention) in India (IM) (CTRI/2017/02/007785)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top